Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma

Multiple myeloma (MM) is a relapsed and refractory disease, one that highlights the need for developing new molecular therapies for overcoming of drug resistance. Addition of panobinostat, a histone deacetylase (HDAC) inhibitor, to bortezomib and dexamethasone improved progression-free survival (PFS...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:JCI Insight
Asıl Yazarlar: Imai, Yoichi, Ohta, Eri, Takeda, Shu, Sunamura, Satoko, Ishibashi, Mariko, Tamura, Hideto, Wang, Yan-hua, Deguchi, Atsuko, Tanaka, Junji, Maru, Yoshiro, Motoji, Toshiko
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society for Clinical Investigation 2016
Konular:
Research Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5033869/
https://ncbi.nlm.nih.gov/pubmed/27699258
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.85061
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller